- Adjusted EBITDA was $280 million, representing a 16.6% margin, down due to gross profit headwinds partially offset by SG&A savings.
- Adjusted EPS was $0.24, a $0.01 decline year-over-year.
- Adjusted gross profit was $554 million with a 32.9% adjusted gross margin, down 130 basis points year-over-year due to price actions, unfavorable mix, and increased supply chain expenses.
- Adjusted net leverage ended at 3.2x adjusted EBITDA, unchanged from Q1.
- Bioprocessing within Bioscience Production was flat year-over-year, with a 5% sequential increase but impacted by customer headwinds and extended maintenance.
- Bioscience Production revenue was $561 million, up 2% organically year-over-year and 7% sequentially.
- Free cash flow was $125 million with 100% adjusted conversion.
- Lab Solutions revenue was $1.122 billion, down 1% organically year-over-year but up 2% sequentially.
- Reported revenue for Q2 was $1.68 billion, flat year-over-year on an organic basis.
Related items and other data are not available for this feed item.
Dafinchi